Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study

Table 6 Outcome in metastatic colorectal cancer patients receiving cetuximab with irinotecan-based chemotherapy from different geographical regions

	ELSIE	LABEL	MABEL	BOND
Reference	Current study	Buzard et al[15]	Wilke et al[14]	Cunningham et al[7]
No. of patients	123	79	1147	218
Geographical region	Asia-Pacific	Latin America	Europe	Europe
Response rate, % (95% CI)	13.8 (8.3-21.2)1	26.6 (17.3-37.7)1	20.1 (17.9-22.6)2	22.9 (17.5-29.1)3
Disease control rate, % (95% CI)	49.6 (40.5-58.8)1	55.7 (44.1-66.9)1	45.2 (42.3-48.2)2	55.5 (48.6-62.2)3
Median PFS, wk (95%CI)	12.1 (9.7-17.7)1	17.4 (11.7-18.9)1	14.1 (13.0-17.1)1	18.0 (12.0-18.0)3
PFS rate at 12 wk, % (95% CI)	50 (41-59)1	57 (46-68)1	61 (58-64)1	564 (48.7-62.6)3
Median survival, mo (95% CI)	9.5 (7.5-11.7)	9.2 (7.9-10.8)	9.2 (8.6-9.8)	8.6 (7.9-9.6)
OS rate at 1 yr, % (95% CI)	38 (29-37)	38 (27-48)	38 (35-41)	29 (22-37)

¹World Health Organisation (WHO) criteria by investigator;

²Subjective assessment by investigator;

³WHO criteria by independent review committee;

⁴In the BOND study the PFS rate was assessed at 3 mo. ELSIE: Erbitux^® pre-License Study In the East; LABEL: Latin American Erbitux Pre-License Study; MABEL: Monoclonal Antibody Erbitux in a European Pre-License Study.